Ligands with its PDB code and its tanimoto calculated from the molecule, present in the database, which has for MMscode: MMs03085047
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
---|---|---|---|---|---|
Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
1BH | N-BENZYLOXYCARBONYL-ALA-PRO-3-AMINO- 4-PHENYL-BUTAN-2-OL | A | 1BH6 | 0.72 | |
BEH | 2,5-DIBENZYLOXY-3,4-DIHYDROXY-HEXANEDIOIC ACID BENZYLAMIDE (2- HYDROXY-INDAN-1-YL)-AMIDE | B | 1D4H | 0.71 | |
009 | (4S)-1,4-dibenzyl-N-[(1S,2R)-1- benzyl-3-{[3-(dimethylamino)benzyl]amino}- 2-hydroxypropyl]-2-oxoimidazolidine- 4-carboxamide | A,B,C | 3CKR | 0.73 | |
216 | [4-R-(4-ALPHA,6-BETA,7-BETA]-HEXAHYDRO- 5,6-DI(HYDROXY)-1,3-DI(ALLYL)-4,7- BISPHENYLMETHYL)-2H-1,3-DIAZEPINONE | B | 1HWR | 0.76 | |
K30 | (2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)- 3-fluoro-1-methylpiperidin-4-yl]- 2-(hydroxymethyl)-N-methyl-2-phenyl- 2,5-dihydro-1H-pyrrole-1-carboxamide | A,B | 3CJO | 0.75 | |
318 | N'-[(1S,2S)-2-[(4S)-1-benzyl-5- oxoimidazolidin-4-yl]-1-(3,5-difluorobenzyl)- 2-hydroxyethyl]-5-methyl-N,N-dipropylbenzene- 1,3-dicarboxamide | A,B | 3CID | 0.72 | |
GB7 | (3R,4R,5R)-3,4-dihydroxy-5-({[(1R)- 2-hydroxy-1-phenylethyl]amino}methyl)- 1-methylpyrrolidin-2-one | A | 3DDG | 0.7 | |
GB2 | (2R,3R,4S)-2-({[(1S)-2-HYDROXY- 1-PHENYLETHYL]AMINO}METHYL)PYRROLIDINE- 3,4-DIOL | A | 2F1A | 0.72 | |
GB3 | (2R,3R,4S,5R)-2-({[(1R)-2-HYDROXY- 1-PHENYLETHYL]AMINO}METHYL)-5-METHYLPYRROLIDINE- 3,4-DIOL | A | 2F1B | 0.71 | |
Q82 | {[4-R(-4-ALPHA,5-ALPHA,6-BETA,7- BETA)]-HEXAHYDRO-5,6-BIS(HYDROXY)- 1,3-BIS(4-HYDROXYMETHYL)METHYL]- 4,7-BIS(PHENYLMETHYL)-2H-1,3-DIAZEPIN- 2-YLIDENE]CYANAMIDE} | B | 1HVH | 0.81 | |
VAC | N,N-BIS(2-HYDROXY-1-INDANYL)-2,6- DIPHENYLMETHYL-4-HYDROXY-1,7-HEPTANDIAMIDE | B | 4PHV | 0.75 | |
DMQ | [4-R-(-4-ALPHA,5-ALPHA,6-BETA,7- BETA)]-HEXAHYDRO-5,6-BIS(HYDROXY)- 1,3-BIS([(3-AMINO)PHENYL]METHYL)- 4,7-BIS(PHENYLMETHYL)-2H-1,3-DIAZEPINONE | B | 1RQ9 | 0.76 | |
DMQ | [4-R-(-4-ALPHA,5-ALPHA,6-BETA,7- BETA)]-HEXAHYDRO-5,6-BIS(HYDROXY)- 1,3-BIS([(3-AMINO)PHENYL]METHYL)- 4,7-BIS(PHENYLMETHYL)-2H-1,3-DIAZEPINONE | A,B | 1DMP | 0.76 | |
DMQ | [4-R-(-4-ALPHA,5-ALPHA,6-BETA,7- BETA)]-HEXAHYDRO-5,6-BIS(HYDROXY)- 1,3-BIS([(3-AMINO)PHENYL]METHYL)- 4,7-BIS(PHENYLMETHYL)-2H-1,3-DIAZEPINONE | A | 1MER | 0.76 | |
GB1 | (2R,3R,4S)-2-({[(1R)-2-HYDROXY- 1-PHENYLETHYL]AMINO}METHYL)PYRROLIDINE- 3,4-DIOL | A | 2F18 | 0.72 | |
OSC | (2R,3AS,6R,7AS)-N-(2-{1-[AMINO(IMINO)METHYL]- 2,5-DIHYDRO-1H-PYRROL-3-YL}ETHYL)- 6-HYDROXY-1-{N-[(2S)-2-HYDROXY- 3-PHENYLPROPANOYL]PHENYLALANYL}OCTAHYDRO- 1H-INDOLE-2-CARBOXAMIDE | B,C,D | 1RIW | 0.71 | |
3QC | (4R)-4-(3-HYDROXYPHENYL)-N,N,7,8- TETRAMETHYL-3,4-DIHYDROISOQUINOLINE- 2(1H)-CARBOXAMIDE | A,B | 2FME | 0.72 | |
BS2 | (3-ENDO,8-ANTI)-8-BENZYL-3-(10,11- DIHYDRO-5H-DIBENZO[A,D][7]ANNULEN- 5-YLOXY)-8-AZONIABICYCLO[3.2.1]OCTANE | A,D,E | 2W8G | 0.7 | |
A88 | (5R,6R)-2,4-BIS-(4-HYDROXY-3-METHOXYBENZYL)- 1,5-DIBENZYL-3-OXO-6-HYDROXY-1,2,4- TRIAZACYCLOHEPTANE | A | 1PRO | 0.73 | |
AAU | (5R,6R)-5-BENZYL-6-HYDROXY-2,4- BIS(4-HYDROXY-3-METHOXYBENZYL)- 1-[3-(4-HYDROXYPHENYL)PROPANOYL]- 1,2,4-TRIAZEPAN-3-ONE | B | 2A4F | 0.7 | |
BH0 | 3-({5-BENZYL-6-HYDROXY-2,4-BIS- (4-HYDROXY-BENZYL)-3-OXO-[1,2,4]- TRIAZEPANE-1-SULFONYL)-BENZONITRILE | B | 1T7K | 0.73 | |
DMP | [4-R-(-4-ALPHA,5-ALPHA,6-BETA,7- BETA)]-HEXAHYDRO-5,6-BIS(HYDROXY)- [1,3-BIS([4-HYDROXYMETHYL-PHENYL]METHYL)- 4,7-BIS(PHENYLMETHYL)]-2H-1,3-DIAZEPINONE | B | 1BVG | 0.89 | |
DMP | [4-R-(-4-ALPHA,5-ALPHA,6-BETA,7- BETA)]-HEXAHYDRO-5,6-BIS(HYDROXY)- [1,3-BIS([4-HYDROXYMETHYL-PHENYL]METHYL)- 4,7-BIS(PHENYLMETHYL)]-2H-1,3-DIAZEPINONE | B | 1MES | 0.89 | |
DMP | [4-R-(-4-ALPHA,5-ALPHA,6-BETA,7- BETA)]-HEXAHYDRO-5,6-BIS(HYDROXY)- [1,3-BIS([4-HYDROXYMETHYL-PHENYL]METHYL)- 4,7-BIS(PHENYLMETHYL)]-2H-1,3-DIAZEPINONE | A | 1MET | 0.89 | |
DMP | [4-R-(-4-ALPHA,5-ALPHA,6-BETA,7- BETA)]-HEXAHYDRO-5,6-BIS(HYDROXY)- [1,3-BIS([4-HYDROXYMETHYL-PHENYL]METHYL)- 4,7-BIS(PHENYLMETHYL)]-2H-1,3-DIAZEPINONE | A,B | 1QBS | 0.89 | |
DMP | [4-R-(-4-ALPHA,5-ALPHA,6-BETA,7- BETA)]-HEXAHYDRO-5,6-BIS(HYDROXY)- [1,3-BIS([4-HYDROXYMETHYL-PHENYL]METHYL)- 4,7-BIS(PHENYLMETHYL)]-2H-1,3-DIAZEPINONE | B | 1BVE | 0.89 | |
DMP | [4-R-(-4-ALPHA,5-ALPHA,6-BETA,7- BETA)]-HEXAHYDRO-5,6-BIS(HYDROXY)- [1,3-BIS([4-HYDROXYMETHYL-PHENYL]METHYL)- 4,7-BIS(PHENYLMETHYL)]-2H-1,3-DIAZEPINONE | A | 1MEU | 0.89 | |
AH1 | AHA001 | A | 1AJX | 0.76 | |
CS7 | N'-[(1S,2R)-2-[(2R,4R)-4-(BENZYLOXY)PYRROLIDIN- 2-YL]-1-(3,5-DIFLUOROBENZYL)-2- HYDROXYETHYL]-5-METHYL-N,N-DIPROPYLISOPHTHALAMIDE | A,B | 2QMD | 0.73 | |
BLL | (2R,3R,4R,5R)-3,4-DIHYDROXY-N,N'- BIS[(1S,2R)-2-HYDROXY-2,3-DIHYDRO- 1H-INDEN-1-YL]-2,5-BIS(2-PHENYLETHYL)HEXANEDIAMIDE | B | 1WBM | 0.73 | |
3TL | BENZYL (2S,5S,8S,9R,10R,11S,14S,17S)- 8,11-DIBENZYL-9,10-DIHYDROXY-5,14- DIISOPROPYL-3,6,13,16-TETRAOXO- 4,7,12,15-TETRAAZAOCTADECANE-2,17- DIYLDICARBAMATE | A,B | 2P3C | 0.73 | |
3TL | BENZYL (2S,5S,8S,9R,10R,11S,14S,17S)- 8,11-DIBENZYL-9,10-DIHYDROXY-5,14- DIISOPROPYL-3,6,13,16-TETRAOXO- 4,7,12,15-TETRAAZAOCTADECANE-2,17- DIYLDICARBAMATE | A | 2P3D | 0.73 | |
3TL | BENZYL (2S,5S,8S,9R,10R,11S,14S,17S)- 8,11-DIBENZYL-9,10-DIHYDROXY-5,14- DIISOPROPYL-3,6,13,16-TETRAOXO- 4,7,12,15-TETRAAZAOCTADECANE-2,17- DIYLDICARBAMATE | A,B | 2P3B | 0.73 | |
3TL | BENZYL (2S,5S,8S,9R,10R,11S,14S,17S)- 8,11-DIBENZYL-9,10-DIHYDROXY-5,14- DIISOPROPYL-3,6,13,16-TETRAOXO- 4,7,12,15-TETRAAZAOCTADECANE-2,17- DIYLDICARBAMATE | A,B | 2P3A | 0.73 | |
XK2 | [4R-(4ALPHA,5ALPHA,6BETA,7BETA)]- HEXAHYDRO-5,6-DIHYDROXY-1,3-BIS[2- NAPHTHYL-METHYL]-4,7-BIS(PHENYLMETHYL)- 2H-1,3-DIAZEPIN-2-ONE | A,B | 1HVR | 0.8 | |
BEG | 2,5-DIBENZYLOXY-3-HYDROXY-HEXANEDIOIC ACID BIS- [(2-HYDROXY-INDAN-1-YL)-AMIDE] | A | 1D4I | 0.7 |